Является ли повышенная частота сердечных сокращений самостоятельным предиктором неблагоприятного прогноза у здоровых людей и пациентов с сердечно-сосудистыми заболеваниями?

1. Azbel MYa. Universal biological scaling and mortality. Proc Natl Acad Sci USA 1994; 91 (26): 12453–7.
2. Levine HJ. Rest heart rate and life expectancy. J Am Coll Cardiol 1997; 30: 1104–6.
3. Kannel WB, Kannel C, Paffenbarger RS et al. Heart rate and cardiovascular mortality: the Framingam study. Am Heart J 1987; 113: 1489–94.
4. Palatini P, Benetos A, Julius S. Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy. Drugs 2006; 66 (2): 133–44.
5. Dalby M, Gjesdal K. Resting pulse rate as an indicator of health and disease. Tidsskr Nor Laegeforen 2012; 132 (11): 1348–51.
6. Jensen MT, Suadicani P, Hein HO, Gyntelberg F. Elevated resting heart rate, physical fitness and all-cause mortality: a 16-year follow-up in the Copenhagen Male Study. Heart 2013; 99 (12): 882–7.
7. Saxena A, Minton D, Lee DC et al. Protective role of resting heart rate on all-cause and cardiovascular disease mortality. Mayo Clin Proc 2013; 88 (12): 1420–6.
8. Roman Pfister, Guido Michels, Stephen J. Sharp, Robert Luben. Resting heart rate and incident heart failure in apparently healthy men and women in the EPIC-Norfolk study. Eur Heart J 2012; 33 (22): 2761–3.
9. Nauman J, Janszky I, Vatten LJ, Wisløff U. Temporal changes in resting heart rate and deaths from ischemic heart disease. JAMA 2011; 306 (23): 2579–87.
10. Piwońska A, Piotrowski W, Broda G, Drygas W. The relationship between resting heart rate and atherosclerosis risk factors. Kardiol Pol 2008; 66 (10): 1069–75.
11. David Nanchen, David J. Stott, Jacobijn Gussekloo et al. Resting heart rate and incident heart failure and cardiovascular mortality in older adults: role of inflammation and endothelial dysfunction: the PROSPER study. Eur J Heart Fail 2013; 15 (5): 581–8.
12. Fox K, Ford I, Steg PG et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372 (9641): 817–21. Doi: 10.1016/S0140-6736(08)61171-X.
13. Reil JC. BEAUTIFUL results – the slower, the better? Lancet 2008. DOI: 10.1016/ S0140-6736 (08) 61172–1
14. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372 (9641): 807–16. Doi: 10.1016/S0140-6736(08)61170-8.
15. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J 2013; (34): 2949–3003.
16. Bangalore S, Messerli FH, Ou FS et al. The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative. Eur Heart J 2010; 31 (5): 552–60.
17. Böhm M, Swedberg K, Komajda M, Borer JS. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376 (9744): 886–94.
18. Bohm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102 (1): 11–22.
19. Greene SJ, Vaduganathan M, Wilcox JE et al. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. JACC Heart Fail 2013; 1 (6): 488–96.
20. Dobre D, Borer JS, Fox K et al. Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heartrate-lowering properties. Eur J Heart Fail 2014; 16 (1): 76–85.
21. Лутай М.И., Лысенко А.Ф. Анализ медикаментозной терапии ишемической болезни сердца в Украине: результаты исследования PULSAR. Укр. кардiол. журн. 2010; (3): 36–43.
22. Orso F, Baldasseroni S, Maggioni AP. Heart rate in coronary syndromes and heart failure. Prog Cardiovasc Dis 2009; 52 (1): 38–45.
23. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. Doi:10.1093/eurheartj/ehs104
24. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013; 81 (7): 379–472.
25. Pepine CJ, Handberg-Thurmond E, Marks P et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an internet – based randomized trial in coronary artery disease patients with hypertension. JACC 1998; 32: 1228–37.
26. Messerli FH, Kupfer S, Pepine CJ. J curve in hypertension and coronary artery disease. Am J Cardiol 2005; 95 (1): 160.
27. Denardo SJ, Gong Y, Nichols WW, Messerli FH. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med 2010; 123 (8): 719–26.
28. Palatini P, Reboldi G, Beilin LJ, Eguchi K. Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. Curr Int J Cardiol 2013; 168 (2): 1490–5.
29. Salles GF, Cardoso CR, Fonseca LL et al. Prognostic significance of baseline heart rate and its interaction with beta-blocker use in resistant hypertension: a cohort study. Am J Hypertens 2013; 26 (2): 218–26.
30. Julius S, Palatini P, Kjeldsen SE, Zanchetti A. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol 2012; 109 (5): 685–92.
31. Okin PM, Kjeldsen SE, Julius S, Hille DA. Effect of changing heart rate during treatment of hypertension on incidence of heart failure. Am J Cardiol 2012; 109 (5): 699–704.
32. Okin PM, Wachtell K, Kjeldsen SE, Julius S. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. Circ Arrhythm Electrophysiol 2008; 1 (5): 337–43.
33. Palatini P, Thijs L, Staessen JA, Fagard RH. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002; 162 (20): 2313–21.
34. Julius S. Tachycardia in hypertension: a saga of progress despite prejudice, confusion, and inertia. Prog Cardiovasc Dis 2009; 52 (1): 26–30.
35. Tjugen TB, Flaa A, Kjeldsen SE. High heart rate as predictor of essential hypertension: the hyperkinetic state, evidence of prediction of hypertension, and hemodynamic transition to full hypertension. Prog Cardiovasc Dis 2009; 52 (1): 20–5.
36. Palatini P, Dorigatti F, Zaetta V, Mormino P. Heart rate as a predictor of development of sustained hypertension in subjects screened for stage 1 hypertension: the HARVEST Study. J Hypertens 2006; 24 (9): 1873–80.
37. Palatini P, Mos L, Santonastaso M et al. Resting heart rate as a predictor of body weight gain in the early stage of hypertension. Obesity (Silver Spring) 2011; 19 (3): 618–23.
38. Palatini P. Elevated heart rate in cardiovascular diseases: a target for treatment? Prog Cardiovasc Dis 2009; 52 (1): 46–60.
39. Рекомендации по лечению артериальной гипертонии. ESH/ESC 2013. Рос. кардиол. журн. 2014; 1: 7–94.

Е.И.Тарловская

ГБОУ ВПО Кировская государственная медицинская академия Минздрава России